NCT04757168

Brief Summary

Despite a decrease in voltage amplitude in post-infarction scar areas, greater voltage amplitudes are sometimes observed at the time of local extrasystoles mechanically induced by catheters. However, no study has investigated whether these electrical changes are associated with mechanical changes in local contractility. However, the voltage is closely correlated to the local contractile function as evidenced by the use of the NOGA system.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 4, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 17, 2021

Completed
1 year until next milestone

Study Start

First participant enrolled

February 23, 2022

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

October 23, 2024

Status Verified

October 1, 2024

Enrollment Period

3.9 years

First QC Date

February 4, 2021

Last Update Submit

October 21, 2024

Conditions

Keywords

stimulation in cardiac scar area

Outcome Measures

Primary Outcomes (1)

  • Evolution of LLS (linear local shortening) via the NOGATM system in percentage

    Study the change in percentage of LLS during stimulation in a post-infarction scar zone identified by voltage mapping of the left ventricle with the NOGA system, compared to LLS in the same zone measured in atrial stimulation

    1month

Secondary Outcomes (3)

  • Evolution of global systolic function: left ventricular ejection fraction

    1month

  • Evolution of the global systolic function: integral time velocity under aortic Translation results Evolution of the global systolic function: integral time velocity under aortic

    1month

  • Evolution of the global systolic function: strain longitudinal global

    1month

Study Arms (1)

NOGA TM probe

EXPERIMENTAL
Device: NOGA TM probe

Interventions

Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient. Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure.

NOGA TM probe

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Patients who should undergo ventricular tachycardia (VT) ablation after a myocardial infarction according to current recommendations, namely: patients with ischemic heart disease (ICD) and with episodes of sustained ventricular tachycardia responsible for internal electric shocks by the implantable automatic defibrillator (ICD) (grade IB recommendation)
  • patients with an MIC and an ICD, presenting a first episode of sustained ventricular tachycardia (grade IIa, B recommendation)
  • Affiliated with a social protection scheme
  • Having signed an informed consent

You may not qualify if:

  • Contraindication or non-indication for ventricular tachycardia ablation
  • Women who are pregnant or of childbearing age and without contraception, breastfeeding women
  • Patients without ischemic heart disease
  • Patients under guardianship, curatorship or legal protection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ROLLIN Anne

Toulouse, CHU de Toulouse, 31059, France

RECRUITING

MeSH Terms

Conditions

Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Officials

  • Anne ROLLIN, MD

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2021

First Posted

February 17, 2021

Study Start

February 23, 2022

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

October 23, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations